Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Effect of different exercise protocols on histone acetyltransferases and histone deacetylases activities in rat hippocampus.

Elsner VR, Lovatel GA, Bertoldi K, Vanzella C, Santos FM, Spindler C, de Almeida EF, Nardin P, Siqueira IR.

Neuroscience. 2011 Sep 29;192:580-7. doi: 10.1016/j.neuroscience.2011.06.066.

PMID:
21745541
2.

Regulation of protein turnover by acetyltransferases and deacetylases.

Sadoul K, Boyault C, Pabion M, Khochbin S.

Biochimie. 2008 Feb;90(2):306-12. Review.

PMID:
17681659
3.

Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.

Anne-Laurence B, Caroline R, Irina P, Jean-Philippe L.

Subcell Biochem. 2007;41:263-93. Review.

PMID:
17484132
4.

Physical and functional HAT/HDAC interplay regulates protein acetylation balance.

Peserico A, Simone C.

J Biomed Biotechnol. 2011;2011:371832. doi: 10.1155/2011/371832. Review.

5.

Impact of protein acetylation in inflammatory lung diseases.

Ito K, Charron CE, Adcock IM.

Pharmacol Ther. 2007 Nov;116(2):249-65. Review.

PMID:
17720252
6.

Histone deacetylation: an important mechanism in inflammatory lung diseases.

Adcock IM, Ito K, Barnes PJ.

COPD. 2005 Dec;2(4):445-55. Review.

PMID:
17147010
7.

Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.

Langley B, Gensert JM, Beal MF, Ratan RR.

Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):41-50. Review.

PMID:
15723612
8.

Roles of histone acetyltransferases and deacetylases in gene regulation.

Kuo MH, Allis CD.

Bioessays. 1998 Aug;20(8):615-26. Review.

PMID:
9780836
9.

Epigenetic regulation of airway inflammation.

Adcock IM, Tsaprouni L, Bhavsar P, Ito K.

Curr Opin Immunol. 2007 Dec;19(6):694-700. Review.

PMID:
17720468
10.

The HAT/HDAC interplay: multilevel control of STAT signaling.

Icardi L, De Bosscher K, Tavernier J.

Cytokine Growth Factor Rev. 2012 Dec;23(6):283-91. doi: 10.1016/j.cytogfr.2012.08.002. Review.

PMID:
22989617
11.
12.

Molecular basis of chronic inflammation in lung diseases: new therapeutic approach.

Mroz RM, Noparlik J, Chyczewska E, Braszko JJ, Holownia A.

J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):453-60. Review.

13.

Acetyltransferases (HATs) as targets for neurological therapeutics.

Schneider A, Chatterjee S, Bousiges O, Selvi BR, Swaminathan A, Cassel R, Blanc F, Kundu TK, Boutillier AL.

Neurotherapeutics. 2013 Oct;10(4):568-88. doi: 10.1007/s13311-013-0204-7. Review.

14.

Histone deacetylases: target enzymes for cancer therapy.

Mottet D, Castronovo V.

Clin Exp Metastasis. 2008;25(2):183-9. Review.

PMID:
18058245
15.
16.

Targeting aberrant transcriptional repression in acute myeloid leukemia.

Moe-Behrens GH, Pandolfi PP.

Rev Clin Exp Hematol. 2003 Jun;7(2):139-59. Review.

PMID:
14763160
17.

Bioanalytical approaches for the detection of protein acetylation-related enzymes.

Li P, Han Y, Li Y, Zhu R, Wang H, Nie Z, Yao S.

Anal Bioanal Chem. 2016 Apr;408(11):2659-68. doi: 10.1007/s00216-016-9304-7. Review.

PMID:
26790874
18.

Acetylation and deacetylation--novel factors in muscle wasting.

Alamdari N, Aversa Z, Castillero E, Hasselgren PO.

Metabolism. 2013 Jan;62(1):1-11. doi: 10.1016/j.metabol.2012.03.019. Review.

19.

Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions.

Sleiman SF, Basso M, Mahishi L, Kozikowski AP, Donohoe ME, Langley B, Ratan RR.

Expert Opin Investig Drugs. 2009 May;18(5):573-84. doi: 10.1517/13543780902810345 . Review.

20.

Humanized animal exercise model for clinical implication.

Seo DY, Lee SR, Kim N, Ko KS, Rhee BD, Han J.

Pflugers Arch. 2014 Sep;466(9):1673-87. doi: 10.1007/s00424-014-1496-0. Review.

PMID:
24647666
Items per page

Supplemental Content

Support Center